Accumulating evidences demonstrate that a population of suppressive cells known as myeloid-derived suppressor cells (MDSCs) is key immune modulators which suppress antitumor immunity. In this study, we found that the level of circulating CD14(+)HLA-DR(-/low) cells in patients was significantly higher than that of healthy donors and was correlated with tumor burden, lymph node metastasis, and tumor, node, and metastasis (TNM) clinical stage. More importantly, we for the first time find the level of CD14(+)HLA-DR(-/low) is a biological indicator of poor prognosis through the analysis of 3-year overall survival. Furthermore, we evidenced that the proportion of CD14(+)HLA-DR(-/low) cells in the tumor metastatic tumor-draining lymph nodes (TDLNs) was notably higher compared to tumor-free TDLNs. Additionally, CD14(+)HLA-DR(-/low) cells from esophageal squamous cell carcinoma (ESCC) patients expressed dramatically increased programmed death ligand 1 (PD-L1) comparing to that from healthy control. Subsequently, blocking PD-L1 pathway by antibody could effectively reverse the suppressive effect on autologous T cell proliferation mediated by CD14(+)HLA-DR(-/low) cells in vitro. In conclusion, our data revealed CD14(+)HLA-DR(-/low) MDSCs which increase in ESCC patients is a novel poor prognostic indicator and may exert immunosuppressive properties through PD-L1/PD-1 pathway.

译文

:越来越多的证据表明,称为髓样抑制细胞(MDSC)的抑制细胞群是抑制抗肿瘤免疫力的关键免疫调节剂。在这项研究中,我们发现患者中循环CD14()HLA-DR(-/ low)细胞的水平显着高于健康供体,并且与肿瘤负荷,淋巴结转移以及肿瘤,淋巴结转移有关。转移(TNM)临床阶段。更重要的是,通过3年总生存期的分析,我们首次发现CD14()HLA-DR(-/低)的水平是预后不良的生物学指标。此外,我们证明在肿瘤转移性肿瘤引流淋巴结(TDLNs)中的CD14()HLA-DR(-/ low)细胞所占的比例明显高于无肿瘤的TDLNs。此外,与健康对照组相比,食管鳞癌(ESCC)患者的CD14()HLA-DR(-/ low)细胞表达的程序性死亡配体1(PD-L1)显着增加。随后,通过抗体阻断PD-L1途径可有效逆转体外对CD14()HLA-DR(-/ low)细胞介导的自体T细胞增殖的抑制作用。总之,我们的数据显示,在ESCC患者中CD14()HLA-DR(-/低)MDSCs增加是一种新的不良预后指标,并且可能通过PD-L1 / PD-1途径发挥免疫抑制作用。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录